ARTICLE | Clinical News
Oral salmon calcitonin: Complete Phase III enrollment
June 8, 2009 7:00 AM UTC
Novartis and Nordic completed enrollment of more than 900 patients ages 51-80 in a 2-year, double-blind, placebo-controlled, international Phase III trial evaluating 0.8 mg of oral SMC021 given twice ...